NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:**  Thursday 16 March 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Stephen Smith (Chair Topic 1) Present for all items
2. Dr Megan John (Chair Topic 2) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Present for all items
5. Professor Rachel Elliott Items 4 to 5.2.2
6. Dr Andrew Hitchings Present for all items
7. Dr Robert Hodgson Items 1 to 4.2.2
8. Dr Bernard Khoo Present for all items
9. Dr Ivan Koychev Present for all items
10. Dr Soo Fon Lim Present for all items
11. Dr Guy Makin Present for all items
12. Dr Philip Mallender Present for all items
13. Professor David Meads Present for all items
14. Dr Nathan Moore Present for all items
15. Dr Malcolm Oswald Present for all items
16. Professor Chris Parker Items 1 to 4.2.2
17. Dr Rebecca Payne Present for all items
18. Carole Pitkeathley Present for all items
19. Dr Raju Reddy Present for all items

NICE staff (key players) present

Jasdeep Hayre, Associate Director Items 1 to 4.2.2

Linda Landells, Associate Director Items 5 to 5.2.2

Celia Mayers, Project Manager Items 1 to 4.2.2

Kate Moore, Project Manager Items 5 to 5.2.2

Victoria Kelly, Heath Technology Assessment Adviser Items 1 to 4.2.2

Lizzie Walker, Heath Technology Assessment Adviser Items 5 to 5.2.2

Rachel Ramsden, Heath Technology Assessment Analyst Items 1 to 4.2.2

Janet Boadu, Heath Technology Assessment Analyst Items 5 to 5.2.2

External assessment group representatives present

Paul Tappenden, School of Health and Related Research (ScHARR), Items 1 to 4.1.3

Kate Ren, School of Health and Related Research (ScHARR), Items 1 to 4.1.3

Matthew Walton, NHS Centre for Reviews and Dissemination and Centre for Health Economics -York, Items 5 to 5.1.3

Clinical & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all Items

Professor Jonathan Wadsley, Consultant Clinical Oncologist, clinical expert nominated by NCRI-ACP-RCP-RCR, Items 1 to 4.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Stephen Smith welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Christopher Herring, Giles Monnickendam, Professor John Watkins and Professor Sofia Dias

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 16 February 2023

### Appraisal of cabozantinib for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [ID4046]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Ipsen.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Clinical expert Professor Jonathan Wadsley declared financial interests as his institution has received payments for him to provide advice and act as speaker for Eisai, Ipsen, Bayer, Roche, AstraZeneca, Sanofi-Genzyme, Novartis (AAA). He has also received research funding from AstraZeneca and Sanofi-Genzyme. It was agreed his declarations would not prevent Professor Wadsley from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Matthew Bradley, Dr Bernard Khoo and Malcolm Oswald.
  1. Part 2 – Closed session (company representatives, clinical expert, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10932>

### Appraisal of lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]

* 1. Part 1 – Open session
     1. The chair Dr Megan John welcomed the NHS England expert, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The chair asked all committee members and expert, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Professor David Meads declared non-financial professional interests as University of Leeds has received funding from Takeda for research in an unrelated area. It was agreed his declaration would not prevent Professor Meads from participating in discussion on this appraisal,
* Committee members Dr Robert Hodgson and Professor Sofia Dias are part of the York EAG team who carried out the assessment for this appraisal, as a direct conflict they did not participate in discussions on this appraisal.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 - Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10812>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 13 April 2023 and will start promptly at 09.30.